- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02774837
Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B (DUAL)
Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Each subject must sign and date a study-specific informed consent form (ICF) prior to their participation in any screening activities. Prospective subjects should be screened no more than 28 days prior to administration of the first dose of study drug on Day 1. Screening evaluations will be used to determine eligibility of each candidate for study enrollment. Subjects meeting all of the inclusion criteria and none of the exclusion criteria as determined during screening will be eligible for the study. Candidates who fail to meet eligibility criteria by screening evaluations may be re-screened one time. Eligible patients at the end of screening will be randomised in a 1:1 ratio to experimental (combination) arm versus control (mono therapy) arm.
Randomisation will be performed by computer generated random codes (performed by Singapore Clinical Research Institute) with a masked allocation sequence. There will be no blinding of therapy and the study will be conducted as an open label study since the outcomes are objectively measurable.
After randomisation patients will be monitored 12 weekly for the first 24 weeks, then every 24 weekly until the last visit at 96 weeks.
At each visit, patients will have a clinical evaluation and have a panel of laboratory tests:
- Hematology: Full blood count, prothrombin time and international normalized ratio
- Chemistry: Sodium, potassium, creatinine, albumin, alkaline phosphatase, -aspartate transaminase, alanine transaminase, lactate dehydrogenase, total bilirubin, creatine phosphokinase, alphafetoprotein,
- Urinalysis: Urine dipstick (Appearance, color, leucocytes, nitrite, urobilinogen, protein, PH, specific gravity, ketone, bilirubin and glucose).
- Viral serology: HBeAg, anti-HBe, HBsAg, qHBsAg and anti-HBs
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 119228
- National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of positive HBsAg or HBV DNA for at least 6 months.
- Documented HBeAg positive or HBeAg negative.
- On any NA (lamivudine, adefovir, entecavir, tenofovir or combination of any of these four) for ≥ 1 year
- HBV DNA viral load ≤1.0 x 10^5 copies/ml at screening
- ALT ≤ 1 x ULN (upper limit normal) U/L
- A transient elastography (Fibroscan®) to evaluate the fibrosis stage will be performed at screening if it is not done in the past 6 months prior to screening. -Patient with compensated cirrhosis are permitted for this study.
- eGFR ≥ 50 mL/min, as calculated by CKI-EPI equation.
- Patient has agreed not to take any other investigational drug or systemic anti-viral, cytotoxic, corticosteroid, immunomodulatory agents or Chinese traditional remedies unless clinically indicated.
- Patient is able to give written consent prior to study start and to comply with the study requirements.
- Women of childbearing potential age must have a negative serum (ß-HCG) pregnancy test taken within 14 days of starting therapy
- Lactating/breastfeeding female subjects must agree to discontinue nursing before initiation of study medication(s).
Exclusion Criteria:
- Evidence of decompensated liver disease defined as direct (conjugated) bilirubin >1.2xULN, prothrombin time (PT) >1.5x upper limit of normal (ULN), serum albumin <35 g/L, or prior history of clinical hepatic decompensation (egs. ascites, encephalopathy, variceal hemorrhage).
- Evidence of hepatocellular carcinoma (HCC).
Have any of the following laboratory tests within 4 weeks of study entry:
- Active co-infection with HIV antibody or HCV antibody or HDV antibody positivity
- Evidence of chronic renal insufficiency as defined by an eGFR (by CKD-EPI equation of < 50 mL/min).
- Previous treatment with any form of interferon, Immunomodulators, systemic cytotoxic agents, or systemic corticosteroids within 6 months prior to screening.
- Prolonged exposure to known hepatotoxins such as alcohol or drugs.
- History of clinically relevant psychiatric disease, seizures, central nervous system dysfunction, severe pre-existing cardiac, renal, hematological disease or medical illness that in the investigator's opinion might interfere with therapy.
- Current or known history of malignant disease within 5 years of trial entry.
- Patients with a history of or currently known muscle related disease.
- Liver or any other organ transplant other than cornea and hair.
- Women who are pregnant and who are not practicing adequate birth control measures, or who are lactating.
- Patients with specific contraindications to study drugs according to their Singapore Package Insert.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: combination
Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks and Telbivudine 600mg oral tablets once daily for 96 weeks
|
Tenofovir disoproxil 300mg once daily for 96 weeks
Other Names:
Telbivudine oral tablets 600mg once daily for 96 weeks
Other Names:
|
Active Comparator: mono therapy
Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks
|
Tenofovir disoproxil 300mg once daily for 96 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
quantitative HBsAg (qHBsAg) reduction >1 log IU/ml
Time Frame: Baseline to week 96
|
Proportion of patients who have a reduction of qHBsAg >1 log IU/ml from baseline to week 96, in experimental arm versus control arm
|
Baseline to week 96
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HBsAg loss
Time Frame: Baseline to week 96
|
Proportion of patients who achieve HBsAg loss at week 96 in experimental versus control arms
|
Baseline to week 96
|
HBsAg seroconversion
Time Frame: Baseline to week 96
|
Proportion of patients who achieve HBsAg seroconversion at week 96 in experimental versus control arms
|
Baseline to week 96
|
HBeAg loss
Time Frame: Baseline to week 96
|
Proportion of patients who achieve HBeAg loss at week 96 in experimental versus control arms
|
Baseline to week 96
|
HBeAg seroconversion
Time Frame: Baseline to week 96
|
Proportion of patients who achieve HBeAg seroconversion at week 96 in experimental versus control arms
|
Baseline to week 96
|
quantitative HBsAg decline by >0.5 log10 IU/mL
Time Frame: Baseline, week 24, 48 and 96
|
Proportion of patients who have a reduction of qHBsAg >0.5 log IU/ml from baseline to week 96, in experimental arm versus control arm
|
Baseline, week 24, 48 and 96
|
Alteration in eGFR
Time Frame: Baseline to week 96
|
Proportion of patients who have an increase in eGFR from baseline to week 96, in experimental arm versus control arm
|
Baseline to week 96
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Seng Gee Lim, MBBS, FRACP, FRCP, MD, FAMS, National University Health System
Publications and helpful links
General Publications
- European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012 Jul;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. Epub 2012 Mar 20. No abstract available. Erratum In: J Hepatol. 2013 Jan;58(1):201. Janssen, Harry [corrected to Janssen, Harry L A].
- Piratvisuth T, Komolmit P, Tanwandee T, Sukeepaisarnjaroen W, Chan HL, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J, Zeuzem S, Cheinquer H, Pathan R, Dong Y, Trylesinski A. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One. 2013;8(2):e54279. doi: 10.1371/journal.pone.0054279. Epub 2013 Feb 4.
- Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology. 2011 Aug;54(2):E1-9. doi: 10.1002/hep.24473.
- Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol. 2011 Nov;55(5):1121-31. doi: 10.1016/j.jhep.2011.06.006. Epub 2011 Jun 28.
- Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, Manns MP, Wedemeyer H, Naoumov NV. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010 Nov;52(5):1611-20. doi: 10.1002/hep.23905.
- Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papatheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2014 Jan;146(1):138-146.e5. doi: 10.1053/j.gastro.2013.09.031. Epub 2013 Sep 22.
- Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, Ghany MG, Hoofnagle JH. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2012 Jun;35(11):1317-25. doi: 10.1111/j.1365-2036.2012.05093.x. Epub 2012 Apr 16.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
- Telbivudine
Other Study ID Numbers
- 2013/00215
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
Clinical Trials on Tenofovir disoproxil
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompleted
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompletedHIV InfectionsSouth Africa, Uganda, Zimbabwe
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV InfectionsUnited States, Puerto Rico
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingDecompensated Heart FailureUnited States
-
CONRADEastern Virginia Medical School; University of North Carolina; Agility Clinical...Completed
-
University of WashingtonBill and Melinda Gates FoundationCompletedHIV Infections | HIV-1 InfectionsKenya, Uganda
-
Samjin Pharmaceutical Co., Ltd.Completed
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedHealthyUnited States
-
Daewoong Pharmaceutical Co. LTD.C&R Research, Inc.CompletedHepatitis B, ChronicKorea, Republic of
-
Samjin Pharmaceutical Co., Ltd.Completed